Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 13th 2014

How Should E-Cigarettes Be Regulated?

Should e-cigarettes be regulated he same way as cigarettes? Should marketing and sales restrictions be the same? Policy and health experts chime-in.

December 13th 2014

Hopkins Adapts to Prevent Cancer Risk of Uterine Morcellation

Just prior to the FDA guidance on the use of power morcellators, Johns Hopkins made public a new care plan for managing fibroids or hysterectomies in women over age 50 years.

December 13th 2014

Making a Case for Biomarkers in Cancer Immunotherapy

Immune response boosters in oncology, approved for melanoma so far, are being evaluated in several different cancer types. While the drugs perform well, there is a definite need to identify responsive patient cohorts.

December 13th 2014

One For Choosing Wisely in Breast Cancer

A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.

December 12th 2014

Oncotype DX DCIS Can Predict Recurrence in Women With DCIS

Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery for DCIS.

December 12th 2014

Cyramza Receives Extended Approval for Advanced NSCLC

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

December 12th 2014

Nashville Star Charles Esten Shares Personal Experience in Battling Rare Blood Disease

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was 2-and-a-half, shares the challenging and painful experiences of battling the disease.

December 11th 2014

Quality of End-of-Life Care for Cancer Patients: Does Home Hospice Care Matter?

Netta Bentur, PhD Shirli Resnizky, MA Ran Balicer, MD Tsofia Eilat-Tsanani, MD

Palliative principles were applied to the care of more HH patients than non-HH patients, but no differences were found in their utilization of healthcare services.

December 11th 2014

Validating Electronic Cancer Quality Measures at Veterans Health Administration

Jeremy B. Shelton, MD, MSHS Ted A. Skolarus, MD, MPH Diana Ordin, MD, MPH Jennifer Malin, MD, PhD AnnaLiza Antonio, MS Joan Ryoo, MD, MSHS Christopher S. Saigal, MD

Even in a fully integrated healthcare system, only 28% of cancer quality measures could be validated by using electronically available data.

December 11th 2014

Slow Adoption of Less Costly, Patient-Preferred Radiation Therapy

Laura Joszt, MA

A majority of breast cancer patients in the US are receiving longer radiation therapy than is necessary and compared with their counterparts in other countries, according to a new study published in JAMA.

December 9th 2014

SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML

Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.

December 9th 2014

EPIC Trial Shows Ponatinib Effective in CML

On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

December 9th 2014

CML Updates: Defining MMR and Results of the DASISION Trial

On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.

December 8th 2014

Giora Sharf Discusses Ways to Represent the CML Patient Voice

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

December 8th 2014

Dr Susanne Saussele Defines When Patients With CML Should Change Therapy

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.

December 8th 2014

Evaluating Safety, Efficacy, and Outcomes of TKIs in CML

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.

December 8th 2014

Jan Geissler Explains Differing Perceptions for Living With CML

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.

December 8th 2014

Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.

December 8th 2014

TKIs and Molecular Response in CML: the EURO-SKI Study

On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the European LeukemiaNet Stop TKI (EURO-SKI) study; the trial used tyrosine kinase inhibitors (TKIs) in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI.

December 8th 2014

Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML

The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.

December 7th 2014

Greg Stephens Offers Advice for the Newly Diagnosed CML Patient

One of the reoccurring themes at the 56th Annual Meeting of the American Society of Hematology was the importance of proper monitoring, said Greg Stephens, executive director of the National CML Society.

December 7th 2014

Dr Elaine Fuchs Explains How Stem Cell Discoveries Fuel Cancer Therapeutics

Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, said Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University.

December 7th 2014

Healthcare Costs in Need of Solutions: Experts at ASH Agree

While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.

December 5th 2014

Dr Mark G. Kris on Use of the Patient's Genome

Recent important changes in oncology have led to major advances that allow providers to recommend very specific therapies, said Mark G. Kris, MD, William and Joy Ruane chair in thoracic oncology at Memorial Sloan Kettering Cancer Center.

December 5th 2014

Markers for Mental Health Problems in Cancer Patients Identified

December 5th 2014

Rapid Progress in Bench-to-Clinic Reported for Several Cancers

The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.

December 4th 2014

340B: A Double-Edged Sword

While ASCO is calling to update the 340B drug discount program, hospitals that serve economically diverse populations make a case for the program: "Because of 340B, we don't have to turn patients away when they can't pay."

December 4th 2014

ASH Adds to the "Choosing Wisely" List

The American Society of Hematology has added 5 more recommendations to it's Choosing Wisely list, which was published in the journal Blood,

December 4th 2014

Xalkori Shows Significant Benefit As First-Line in ALK-Positive NSCLC

The study, published in NEJM, found that PFS improved by nearly 4 months while ORR improved by nearly 30%.

December 4th 2014

Prostate Cancer Diagnostic Test Could Prevent Over or Under Treatment

By distinguishing low- and intermediate-risk patients, Oncotype DX is predicted to avoid over- and under-treatment of prostate cancer patients.

...

143 144 145 146 147 148 149 150 151

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions